Please login to the form below

blood cancer

This page shows the latest blood cancer news and features for those working in and with pharma, biotech and healthcare.

Roche’s Lunsumio granted Priority Review by FDA for people with relapsed or refractory follicular lymphoma

$Roche’s Lunsumio granted Priority Review by FDA for people with relapsed or refractory follicular lymphoma$

Follicular lymphoma is the most common, slow-growth type of non-Hodgkin lymphoma (NHL) – a form of blood cancer – which often returns after a first therapy. ... The FDA is expected to decide on the approval of the novel cancer immunotherapy by 29

Latest news

Novartis’ Kymriah receives FDA approval to treat follicular lymphoma

Although follicular lymphoma is commonly an indolent type of cancer – a form that is slow to progress and does not pose an immediate threat – there are a number of treatments available ... outcomes. “Having this single infusion treatment option
Roche’s Polivy receives EC approval for lymphoma therapy

The complex treatment also incorporates cyclophosphamide, doxorubicin and prednisone (R-CHP). Every year in Europe approximately 40, 000 people are diagnosed with DLBCL, a very aggressive form of blood cancer.
EC approves Novartis’ Kymriah for advanced blood cancer

blood cancer, after two or more lines of systemic therapy. ... With this approval, we are pleased to be able to offer this transformative therapy to more people across the globe living with this advanced blood cancer,” added Marie-France Tschudin,
Kite’s new CAR T-cell therapy manufacturing facility given the go-ahead by the FDA

The site in the US will produce CAR T-cell therapies for patients with blood cancers. ... CAR T-cell therapy is unlike other cancer treatments as it is a one-time treatment.
$Janssen and Legend Biotech’s Carvykti receives FDA approval for patients with relapsed or refractory multiple myeloma$ Janssen and Legend Biotech’s Carvykti receives FDA approval for patients with relapsed or refractory multiple myeloma

Multiple myeloma is an incurable blood cancer that impacts plasma cells – a type of white blood cell – which are found in the bone marrow.

More from news
Approximately 10 fully matching, plus 257 partially matching documents found.

Latest Intelligence

Patient diversity in clinical trials needs to be centre stage

For example, a few years back we created clinical trial advertising materials for a Triple Negative Breast Cancer study project and, as the condition adversely impacts the black population, we made ... opportunities.”. A blood cancer charity recently
20 for 2020 – Five pharma companies to watch

The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... BMS will become the fourth largest pharma firm by sales – behind Pfizer, Novartis and Roche – and the addition of
Cell and gene therapy

patient.”. Althoff cites Novartis’ Kymriah (tisagenlecleucel), a blood cancer cell therapy approved in Europe and the US last year, as an example of the differing manufacturing costs.
Drug launches to watch in 2019

These include Pfizer’s Daurismo, the first smoothened (SMO) receptor inhibitor to be approved for blood cancer. ... In patients with non-metastatic CRPC, there is a high unmet need to delay development of metastases and the progression to advanced
The handover: Pfizer reshapes itself for a new era

Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... Breast cancer drug Ibrance will be one of the biggest growth drivers for the company, as it looks

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest appointments

Kiadis Pharma appoints Vincent Brichard to supervisory board

Kiadis has a focus on research, development and commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders, including its lead product Atir. ... Atir achieved some extremely compelling clinical
Kiadis Pharma appoints chief medical officer

I believe ATIR is a truly innovative product and has the potential to become a key part of the next generation treatments of blood cancers.”. ... family members as donors for patients suffering from blood cancer.
Astellas poaches new oncology head from Takeda

She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche. ... At Millennium Dr Thom will have worked on Velcade, a drug co-developed with
Cellerant appoints William Reed as VP clinical development

Will lead development of stem cell-based treatments for blood conditions and cancer. ... Dr Reed joins from Cerus Corporation and will lead the development of Cellerant's stem cell-based cellular and antibody therapies for blood disorders and cancer.
Bayer’s Jörg Reinhardt to replace Daniel Vasella as Novartis chair

Novartis also launched key products, such as cancer treatment Gllevec/Glivec (imatinib) and blood pressure medicine Tekturna (aliskiren), during Dr Vasella's time in charge.

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

Abbie's (associate copywriter) first 6-months at COUCH Health

I covered biological mechanisms of how chemotherapy works, what cancer actually is, and different mechanisms of detecting cancer in the blood.
Brain tumour awareness month: giving research a more humane face

And yet, only 1% of the national spend on cancer research is allocated to this devastating disease. ... Zaynah Maherally and their team have been developing the first cutting-edge, animal free, 3D model of the blood-brain barrier.
Frontera wins at IPA Best of Health 2016

This art installation allows those affected by blood cancer to let out their hidden thoughts and see how the ELF Mind and Body Service is able to support them.
The other side of … blood cancer

The other side of … blood cancer. “I’m so sick of chasing him down the hospital corridors. ... The environment is certainly one challenge – busy hospital, many blood cancer patients, so her doctor’s time is limited.
In the precision medicine era, the line between products and services is blurred

target the cancer cells and infusing them back into the patient’s body. ... The CAR-T treatment pathway for a blood cancer involves a uniquely large number of stakeholders, touchpoints and interdependent processes that take place both in the front-end